Companies › KLRS

Kalaris Therapeutics Inc (KLRS)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001754068 · EDGAR filings · Updated 2026-07-27

Kalaris Therapeutics Inc (KLRS) has reported institutional ownership of 81.0%, with 58 institutional managers holding positions valued at $107.2M per the latest 13F reporting period.

Filings this week (1)

• 2026-07-27 — Initial insider ownership filed (Form 3)

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-20 — Insider transaction reported (Form 4)
• 2026-07-20 — Initial insider ownership filed (Form 3)
• 2026-07-20 — Current report (8-K) filed
• 2026-07-17 — Current report (8-K) filed
• 2026-07-06 — Current report (8-K) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, Kalaris Therapeutics Inc has 58 institutional holders and institutional ownership of 81.0%.

Insider activity

Insiders reported 3 transactions (1 buys, 1 sells) across 3 reporting insiders, with a net reported value of $4.99M.

Related companies

SHOULDER INNOVATIONS INC (SI) · ACUMEN PHARMACEUTICALS INC (ABOS) · ARTIVA BIOTHERAPEUTICS INC (ARTV) · PRELUDE THERAPEUTICS INC (PRLD) · ELECTROMED INC (ELMD) · SILENCE THERAPEUTICS PLC (SLN)